In preclinical models, mice with prolactinomas lacking the dopamine 2 receptor (D2R) exhibited higher VEGF levels, which were subsequently reduced with anti-VEGF treatment, leading to decreased tumor size, vascularity, and prolactin levels (78, 79). The gene discussed is DRD2; the disease is neoplasm.